Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06570824 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

rTMS as an Intervention for Levodopa-induced Dyskinesia

Study acronym: ADAPT-LIDI
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jul 22, 2024 to Aug 22, 2024
    • Study completion pushed from May 1, 2027 to Dec 1, 2027
    v3
  2. Eligibility criteria shortened, about 16 words
    • Study description expanded, about 8 words
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The proposed study investigates the use of repetitive transcranial magnetic stimulation (rTMS) as a treatment for levodopa-induced dyskinesia (LID) in Parkinson's Disease (PD). Specifically, the study aims to determine whether patterned stimulation of the pre-supplementary motor area (pre-SMA) can delay the onset of LID after levodopa intake and reduce LID severity in PD patients. This study will provide critical insights into potential targets for rTMS treatment, optimal rTMS parameters, and the mechanisms underlying LID in Parkinson's disease.
Trial Details
NCT Number NCT06570824
Lead Sponsor Danish Research Centre for Magnetic Resonance
Conditions
(from sponsor)		 Dyskinesia, Drug-Induced, Parkinson Disease
Related terms Basal Ganglia Diseases, Central Nervous System Diseases, Dyskinesia, Drug-Induced, Dyskinesias, Movement Disorders, Neurodegenerative Diseases, Parkinson Disease, Synucleinopathies
Enrollment 68 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov